Titre : Hémoglobinurie

Hémoglobinurie : Questions médicales fréquentes

Termes MeSH sélectionnés :

Disorders of Excessive Somnolence
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Hémoglobinurie : Questions médicales les plus fréquentes", "headline": "Hémoglobinurie : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Hémoglobinurie : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-28", "dateModified": "2025-02-22", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Hémoglobinurie" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Protéinurie", "url": "https://questionsmedicales.fr/mesh/D011507", "about": { "@type": "MedicalCondition", "name": "Protéinurie", "code": { "@type": "MedicalCode", "code": "D011507", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C23.888.942.750" } } }, "about": { "@type": "MedicalCondition", "name": "Hémoglobinurie", "alternateName": "Hemoglobinuria", "code": { "@type": "MedicalCode", "code": "D006456", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Hubert Schrezenmeier", "url": "https://questionsmedicales.fr/author/Hubert%20Schrezenmeier", "affiliation": { "@type": "Organization", "name": "Institute of Transfusion Medicine, University of Ulm, Ulm, Germany." } }, { "@type": "Person", "name": "Austin G Kulasekararaj", "url": "https://questionsmedicales.fr/author/Austin%20G%20Kulasekararaj", "affiliation": { "@type": "Organization", "name": "From the Hematology and Transplant Unit, French Reference Center for Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria, Saint-Louis Hospital (R.P.L., F.S.F.), and Université de Paris (R.P.L.), Paris, Centre Hospitalier Universitaire (CHU) de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse (S.T.), and CHU Lille, Université de Lille, Lille (L.T.) - all in France; the Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen (A.R., F.A.), the Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, University Hospital RWTH Aachen, and the Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, Aachen (J.P.), the University of Ulm, the Institute of Transfusion Medicine and Immunogenetics, German Red Cross Blood Transfusion Service Baden-Württemberg-Hessen, and University Hospital Ulm, Ulm (H.S., B. Höchsmann), the Department of Oncology, Hematology, and Bone Marrow Transplantation, Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg (P. Schafhausen), and Elblandklinikum Riesa, Riesa (J.S.) - all in Germany; King's College Hospital NHS Foundation Trust (A.G.K., S.G., R.T.), the National Institute for Health and Care Research and Wellcome King's Clinical Research Facility (A.G.K.), King's College London (A.G.K.), and Novartis Pharmaceuticals (C.T.), London, and St. James's University Hospital, Leeds (M.G., R.J.K.) - all in the United Kingdom; Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College, Beijing (B. Han, C.Y.), the Department of Hematology, Tianjin Medical University General Hospital (R.F., H.L.), and the Department of Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (L.Z.), Tianjin, and China Novartis Institutes for BioMedical Research, Shanghai (Z.W., S.L.) - all in China; the Division of Hematology, Hospital A Beneficência Portuguesa, São Paulo (P. Scheinberg), and ABC Medical School, Santo André (V.A.Q.M.) - both in Brazil; the Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland (J.P.M.); Osaka University Graduate School of Medicine, Suita (Y.U.), Kyoto University Hospital, Kyoto (T.K.), and Japanese Red Cross Society Suwa Hospital, Suwa (M.U.) - all in Japan; Duke University School of Medicine and Duke Cancer Institute, Durham, NC (C.M.C.); Unità Operativa Complessa Oncoematologia, AULSS7 Pedemontana, Bassano del Grappa (E.D.B.), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan (W.B.), Division of Hematology, University of Turin, Città della Salute e della Scienza, Turin (E.B.), Instituto per lo Studio, la Prevenzione e la Rete Oncologica, and Azienda Ospedaliero-Universitaria Careggi, Florence (R.N.), AORN Moscati, Avellino (L.M., A.M.R.), and University of Naples Federico II, Naples (A.M.R.) - all in Italy; Radboud University Medical Center, Nijmegen, the Netherlands (S.M.C.L.); the Hematology Unit, Department of Medicine, Hospital Umum Sarawak, Kuching (L.P.C.), and the Hematology Unit, Queen Elizabeth Hospital, Kota Kinabalu (L.W.L.L.) - both in Malaysia; Hospital Clinic of Barcelona (A.G.) and the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Transplantation (R.P.L., A.G.K., M.G., W.B., S.T., L.T., F.S.F., L.M., A.M.R.) - both in Barcelona; the Department of Hematology and Oncology and the Department of Clinical Pathology, Hualien Tzu Chi Hospital, the Buddhist Tzu Chi Medical Foundation, and the Institute of Medical Sciences, Tzu Chi University, Hualien, Taiwan (W.-H.H.); the Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea (J.H.J.); Medical College of Georgia, Augusta (A.K.); City of Hope Medical Center, Duarte, CA (V.P.); the Department of Laboratory Medicine, National University Hospital, Singapore (E.-S.Y.); Novartis Pharma (C.K., R.L., M.D.) and Novartis BioMedical Research (A.V.) - both in Basel, Switzerland; and Novartis Healthcare Private, Hyderabad, India (P.B., R.K., S.M.)." } }, { "@type": "Person", "name": "Robert A Brodsky", "url": "https://questionsmedicales.fr/author/Robert%20A%20Brodsky", "affiliation": { "@type": "Organization", "name": "Division of Hematology, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD." } }, { "@type": "Person", "name": "Jun-Ichi Nishimura", "url": "https://questionsmedicales.fr/author/Jun-Ichi%20Nishimura", "affiliation": { "@type": "Organization", "name": "Osaka University Graduate School of Medicine, Department of Hematology and Oncology." } }, { "@type": "Person", "name": "Britta Höchsmann", "url": "https://questionsmedicales.fr/author/Britta%20H%C3%B6chsmann", "affiliation": { "@type": "Organization", "name": "Institute of Transfusion Medicine, University of Ulm, Ulm, Germany." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Excessive daytime sleepiness, morning tiredness, and prognostic biomarkers in patients with chronic coronary syndrome.", "datePublished": "2023-09-23", "url": "https://questionsmedicales.fr/article/37748524", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ijcard.2023.131395" } }, { "@type": "ScholarlyArticle", "name": "Health-related impact of illness associated with excessive daytime sleepiness in patients with obstructive sleep apnea.", "datePublished": "2023-05-02", "url": "https://questionsmedicales.fr/article/37129416", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1080/00325481.2023.2203623" } }, { "@type": "ScholarlyArticle", "name": "Solriamfetol treatment of excessive daytime sleepiness in participants with narcolepsy or obstructive sleep apnea with a history of depression.", "datePublished": "2022-08-20", "url": "https://questionsmedicales.fr/article/36070638", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.jpsychires.2022.08.018" } }, { "@type": "ScholarlyArticle", "name": "Major depressive episode with insomnia and excessive daytime sleepiness: A more homogeneous and severe subtype of depression.", "datePublished": "2023-11-11", "url": "https://questionsmedicales.fr/article/37979319", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.psychres.2023.115603" } }, { "@type": "ScholarlyArticle", "name": "Recommendations for clinical management of excessive daytime sleepiness in obstructive sleep apnoea - A Delphi consensus study.", "datePublished": "2023-10-09", "url": "https://questionsmedicales.fr/article/37839271", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.sleep.2023.10.001" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "États, signes et symptômes pathologiques", "item": "https://questionsmedicales.fr/mesh/D013568" }, { "@type": "ListItem", "position": 3, "name": "Signes et symptômes", "item": "https://questionsmedicales.fr/mesh/D012816" }, { "@type": "ListItem", "position": 4, "name": "Manifestations urologiques", "item": "https://questionsmedicales.fr/mesh/D020924" }, { "@type": "ListItem", "position": 5, "name": "Protéinurie", "item": "https://questionsmedicales.fr/mesh/D011507" }, { "@type": "ListItem", "position": 6, "name": "Hémoglobinurie", "item": "https://questionsmedicales.fr/mesh/D006456" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Hémoglobinurie - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Hémoglobinurie", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-08", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Hémoglobinurie", "description": "Comment diagnostiquer l'hémoglobinurie ?\nQuels tests sont utilisés pour confirmer l'hémoglobinurie ?\nQuels signes indiquent une hémoglobinurie ?\nL'hémoglobinurie est-elle visible à l'œil nu ?\nQuels autres tests peuvent être nécessaires ?", "url": "https://questionsmedicales.fr/mesh/D006456?mesh_terms=Disorders+of+Excessive+Somnolence&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Hémoglobinurie", "description": "Quels sont les symptômes de l'hémoglobinurie ?\nL'hémoglobinurie cause-t-elle des douleurs ?\nPeut-on avoir de la fièvre avec l'hémoglobinurie ?\nL'hémoglobinurie entraîne-t-elle une anémie ?\nY a-t-il des signes urinaires associés ?", "url": "https://questionsmedicales.fr/mesh/D006456?mesh_terms=Disorders+of+Excessive+Somnolence&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Hémoglobinurie", "description": "Comment prévenir l'hémoglobinurie ?\nLes infections urinaires peuvent-elles être évitées ?\nY a-t-il des mesures spécifiques pour les athlètes ?\nLes maladies héréditaires peuvent-elles être évitées ?\nL'alimentation joue-t-elle un rôle ?", "url": "https://questionsmedicales.fr/mesh/D006456?mesh_terms=Disorders+of+Excessive+Somnolence&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Hémoglobinurie", "description": "Comment traiter l'hémoglobinurie ?\nLes transfusions sont-elles nécessaires ?\nDes médicaments peuvent-ils aider ?\nL'hydratation est-elle importante ?\nQuand consulter un médecin pour l'hémoglobinurie ?", "url": "https://questionsmedicales.fr/mesh/D006456?mesh_terms=Disorders+of+Excessive+Somnolence&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Hémoglobinurie", "description": "Quelles complications peuvent survenir ?\nL'hémoglobinurie peut-elle endommager les reins ?\nY a-t-il un risque d'infection ?\nDes problèmes cardiovasculaires peuvent-ils survenir ?\nL'hémoglobinurie peut-elle être fatale ?", "url": "https://questionsmedicales.fr/mesh/D006456?mesh_terms=Disorders+of+Excessive+Somnolence&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Hémoglobinurie", "description": "Quels sont les facteurs de risque de l'hémoglobinurie ?\nLes athlètes sont-ils plus à risque ?\nLes maladies génétiques augmentent-elles le risque ?\nCertains médicaments sont-ils des facteurs de risque ?\nL'âge influence-t-il le risque d'hémoglobinurie ?", "url": "https://questionsmedicales.fr/mesh/D006456?mesh_terms=Disorders+of+Excessive+Somnolence&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer l'hémoglobinurie ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Un test urinaire détecte l'hémoglobine libre, souvent accompagné d'analyses sanguines." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour confirmer l'hémoglobinurie ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de laboratoire comme l'analyse d'urine et la numération des globules rouges sont utilisés." } }, { "@type": "Question", "name": "Quels signes indiquent une hémoglobinurie ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Une urine de couleur rouge ou brune, associée à des douleurs abdominales, peut indiquer l'hémoglobinurie." } }, { "@type": "Question", "name": "L'hémoglobinurie est-elle visible à l'œil nu ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'urine peut apparaître rougeâtre ou brunâtre, mais des tests sont nécessaires pour confirmation." } }, { "@type": "Question", "name": "Quels autres tests peuvent être nécessaires ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Des tests pour évaluer la fonction rénale et rechercher des infections peuvent être requis." } }, { "@type": "Question", "name": "Quels sont les symptômes de l'hémoglobinurie ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent urine colorée, douleurs abdominales et fatigue, selon la cause." } }, { "@type": "Question", "name": "L'hémoglobinurie cause-t-elle des douleurs ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des douleurs abdominales ou lombaires peuvent accompagner l'hémoglobinurie." } }, { "@type": "Question", "name": "Peut-on avoir de la fièvre avec l'hémoglobinurie ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une fièvre peut survenir si l'hémoglobinurie est causée par une infection sous-jacente." } }, { "@type": "Question", "name": "L'hémoglobinurie entraîne-t-elle une anémie ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la destruction des globules rouges peut provoquer une anémie, entraînant fatigue et faiblesse." } }, { "@type": "Question", "name": "Y a-t-il des signes urinaires associés ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des signes comme des mictions fréquentes ou douloureuses peuvent être présents avec l'hémoglobinurie." } }, { "@type": "Question", "name": "Comment prévenir l'hémoglobinurie ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Évitez les traumatismes, les infections et maintenez une bonne hydratation pour prévenir l'hémoglobinurie." } }, { "@type": "Question", "name": "Les infections urinaires peuvent-elles être évitées ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une bonne hygiène et une hydratation adéquate aident à prévenir les infections urinaires." } }, { "@type": "Question", "name": "Y a-t-il des mesures spécifiques pour les athlètes ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les athlètes doivent éviter les blessures et bien s'hydrater pour prévenir l'hémoglobinurie." } }, { "@type": "Question", "name": "Les maladies héréditaires peuvent-elles être évitées ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Non, mais un suivi médical régulier peut aider à gérer les risques associés aux maladies héréditaires." } }, { "@type": "Question", "name": "L'alimentation joue-t-elle un rôle ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation équilibrée peut renforcer le système immunitaire et réduire les risques d'infections." } }, { "@type": "Question", "name": "Comment traiter l'hémoglobinurie ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement dépend de la cause sous-jacente, incluant transfusions ou médicaments." } }, { "@type": "Question", "name": "Les transfusions sont-elles nécessaires ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Des transfusions peuvent être nécessaires si l'hémoglobinurie cause une anémie sévère." } }, { "@type": "Question", "name": "Des médicaments peuvent-ils aider ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des médicaments pour traiter l'infection ou la maladie sous-jacente peuvent être prescrits." } }, { "@type": "Question", "name": "L'hydratation est-elle importante ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une bonne hydratation aide à diluer l'urine et à réduire les symptômes de l'hémoglobinurie." } }, { "@type": "Question", "name": "Quand consulter un médecin pour l'hémoglobinurie ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Consultez un médecin si vous avez une urine colorée ou des symptômes associés persistants." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des complications incluent l'anémie sévère, des lésions rénales et des infections urinaires." } }, { "@type": "Question", "name": "L'hémoglobinurie peut-elle endommager les reins ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une hémoglobinurie prolongée peut entraîner des lésions rénales et une insuffisance rénale." } }, { "@type": "Question", "name": "Y a-t-il un risque d'infection ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'hémoglobinurie peut augmenter le risque d'infections urinaires et rénales." } }, { "@type": "Question", "name": "Des problèmes cardiovasculaires peuvent-ils survenir ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une anémie sévère due à l'hémoglobinurie peut entraîner des problèmes cardiovasculaires." } }, { "@type": "Question", "name": "L'hémoglobinurie peut-elle être fatale ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Dans de rares cas, des complications graves peuvent survenir, rendant la situation potentiellement fatale." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque de l'hémoglobinurie ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les traumatismes, infections, maladies héréditaires et certains médicaments augmentent le risque." } }, { "@type": "Question", "name": "Les athlètes sont-ils plus à risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les athlètes peuvent être à risque en raison de traumatismes répétés et de déshydratation." } }, { "@type": "Question", "name": "Les maladies génétiques augmentent-elles le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des maladies comme la drépanocytose augmentent le risque d'hémoglobinurie." } }, { "@type": "Question", "name": "Certains médicaments sont-ils des facteurs de risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains médicaments comme les antibiotiques peuvent provoquer une hémoglobinurie." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque d'hémoglobinurie ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes âgées peuvent être plus à risque en raison de maladies sous-jacentes." } } ] } ] }

Sources (10000 au total)

Excessive daytime sleepiness, morning tiredness, and prognostic biomarkers in patients with chronic coronary syndrome.

Sleep-related breathing disorders (SRBD) are related to cardiovascular outcomes in patients with chronic coronary syndrome (CCS). Whether SRBD-related symptoms are associated with prognostic biomarker... Associations between frequency (never/rarely, sometimes, often, always) of self-reported SRBD-related symptoms (excessive daytime sleepiness [EDS]; morning tiredness [MT]; loud snoring; multiple awake... EDS was associated (geometric mean ratio, 95% confidence interval) with increased levels of IL-6 (often 1.07 [1.03-1.10], always 1.15 [1.10-1.21]), GDF-15 (often 1.03 [1.01-1.06], always 1.07 [1.03-1.... In patients with CCS, stepwise increased frequency of SRBD-related symptoms, such as EDS and MT, were associated with gradually higher levels of IL-6 and GDF-15, each reflecting distinct pathophysiolo...

Health-related impact of illness associated with excessive daytime sleepiness in patients with obstructive sleep apnea.

This real-world study aimed to characterize the impact of illness of excessive daytime sleepiness (EDS) in patients with obstructive sleep apnea (OSA) who are adherent to continuous positive airway pr... This cross-sectional study surveyed participants in Evidation Health's Achievement app (November 2020-January 2021), a mobile consumer platform that encourages users to develop healthy habits and prov... In total, 476 participants (female,... EDS influences choices related to physical activity, caffeine consumption, and diet in patients who are adherent with CPAP. More research is needed to understand the association between EDS and choice...

Solriamfetol treatment of excessive daytime sleepiness in participants with narcolepsy or obstructive sleep apnea with a history of depression.

Given the high rate of depression associated with narcolepsy or obstructive sleep apnea (OSA), this analysis compared effects of solriamfetol treatment of excessive daytime sleepiness (EDS) in partici...

Major depressive episode with insomnia and excessive daytime sleepiness: A more homogeneous and severe subtype of depression.

Previous studies have noted the crucial role of excessive daytime sleepiness (EDS) in the course of depressive illness, and more recently, a few studies documented its strong associations with an incr...

Recommendations for clinical management of excessive daytime sleepiness in obstructive sleep apnoea - A Delphi consensus study.

Excessive daytime sleepiness is common with obstructive sleep apnoea and can persist despite efforts to optimise primary airway therapy. The literature lacks recommendations regarding differential dia... A panel of 10 international experts was convened to undertake a modified Delphi process. Statements were developed based on available evidence identified through a scoping literature review, and exper... Consensus was achieved for 32 final statements. The panel agreed excessive daytime sleepiness is a patient-reported symptom. The importance of subjective/objective evaluation of excessive daytime slee... Excessive daytime sleepiness in patients with obstructive sleep apnoea is a public health issue requiring increased awareness, recognition, and attention. Implementation of these statements may improv...

Effects of solriamfetol on on-the-road driving performance in participants with excessive daytime sleepiness associated with obstructive sleep apnoea.

To evaluate the impact of solriamfetol, a dopamine and norepinephrine reuptake inhibitor, on on-the-road driving in participants with excessive daytime sleepiness (EDS) associated with obstructive sle... Eligible participants were aged 21-75 years with OSA and EDS (Maintenance of Wakefulness Test mean sleep latency <30 minutes and Epworth Sleepiness Scale score ≥10). Participants were randomised 1:1 t... Solriamfetol significantly reduced SDLP at 2 (n = 34; least squares mean difference, -1.1 cm; 95% CI, -1.85, -0.32; p = 0.006) and 6 hours postdose (n = 32; least squares mean difference, -0.8 cm; 95%... Solriamfetol 300 mg/day significantly improved on-the-road driving performance in participants with EDS associated with OSA....

Prevalence, dimensions, and correlates of excessive daytime sleepiness in community-dwelling older adults: the Yilan study, Taiwan.

Daytime sleepiness is an important health problem. However, the dimensionality of the Epworth Sleepiness Scale (ESS) in older adults remains unclear. This study aimed to determine the prevalence of ES... This is a community-based survey in which community-dwelling older adults aged ≥ 65 years participated. Excessive daytime sleepiness was assessed using the ESS and was defined as an ESS score of > 10.... In total, 3978 older adults participated in this study. The mean age was 76.6 ± 6.7 years, with 53.8% ≥ 75 years, and 57.1% were female. The prevalence of ESS-defined excessive daytime sleepiness was ... The prevalence of ESS-defined excessive daytime sleepiness is high, and its correlates vary among older adults. This study also suggests a dual ESS structure in community-dwelling older adults....

Calcium, magnesium, potassium, and sodium oxybates oral solution for cataplexy or excessive daytime sleepiness associated with narcolepsy.

Lower-sodium oxybate (LXB) is a novel formulation that is approved by the US Food and Drug Administration (FDA) to treat cataplexy and excessive daytime sleepiness (EDS) in adult patients and children... This drug review discusses narcolepsy, current and upcoming pharmacotherapy, and LXB chemistry, pharmacodynamics, pharmacokinetics, and metabolism. Published results from LXB's phase 1 studies, a phas... LXB is efficacious in treating daytime sleepiness and cataplexy in adults and children ≥7 years with narcolepsy. Using LXB instead of SXB formulations may benefit narcolepsy patients with cardiovascul...

The prevalence and predictors of poor sleep quality and excessive daytime sleepiness in epilepsy: A single tertiary centre experience in Malaysia.

People with epilepsy frequently encounter sleep disruptions that can stem from a variety of complex factors. Epilepsy-related sleep disturbance can lead to reduced quality of life and excessive daytim... A cross-sectional study on 284 epilepsy patients was performed in a local tertiary centre. The demographic and clinical epilepsy data were collected. The Pittsburgh Sleep Quality Index (PSQI) and Epwo... Poor sleep quality was reported in 78 (27.5%) patients while daytime hypersomnolence was present in 17 (6%) patients. The predictors of poor sleep quality include structural causes (OR = 2.749; 95% CI... Sleep disturbances frequently coexist with epilepsy. Patients should be actively evaluated using the PSQI and ESS questionnaires. It is imperative to identify the key factors that lead to reduced slee...